Cargando…
Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q
The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.61...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473269/ https://www.ncbi.nlm.nih.gov/pubmed/34578275 http://dx.doi.org/10.3390/v13091693 |
_version_ | 1784574949727404032 |
---|---|
author | Wilhelm, Alexander Toptan, Tuna Pallas, Christiane Wolf, Timo Goetsch, Udo Gottschalk, Rene Vehreschild, Maria J. G. T. Ciesek, Sandra Widera, Marek |
author_facet | Wilhelm, Alexander Toptan, Tuna Pallas, Christiane Wolf, Timo Goetsch, Udo Gottschalk, Rene Vehreschild, Maria J. G. T. Ciesek, Sandra Widera, Marek |
author_sort | Wilhelm, Alexander |
collection | PubMed |
description | The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together. |
format | Online Article Text |
id | pubmed-8473269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84732692021-09-28 Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q Wilhelm, Alexander Toptan, Tuna Pallas, Christiane Wolf, Timo Goetsch, Udo Gottschalk, Rene Vehreschild, Maria J. G. T. Ciesek, Sandra Widera, Marek Viruses Communication The capacity of convalescent and vaccine-elicited sera and monoclonal antibodies (mAb) to neutralize SARS-CoV-2 variants is currently of high relevance to assess the protection against infections. We performed a cell culture-based neutralization assay focusing on authentic SARS-CoV-2 variants B.1.617.1 (Kappa), B.1.617.2 (Delta), B.1.427/B.1.429 (Epsilon), all harboring the spike substitution L452R. We found that authentic SARS-CoV-2 variants harboring L452R had reduced susceptibility to convalescent and vaccine-elicited sera and mAbs. Compared to B.1, Kappa and Delta showed a reduced neutralization by convalescent sera by a factor of 8.00 and 5.33, respectively, which constitutes a 2-fold greater reduction when compared to Epsilon. BNT2b2 and mRNA1273 vaccine-elicited sera were less effective against Kappa, Delta, and Epsilon compared to B.1. No difference was observed between Kappa and Delta towards vaccine-elicited sera, whereas convalescent sera were 1.51-fold less effective against Delta, respectively. Both B.1.617 variants Kappa (+E484Q) and Delta (+T478K) were less susceptible to either casirivimab or imdevimab. In conclusion, in contrast to the parallel circulating Kappa variant, the neutralization efficiency of convalescent and vaccine-elicited sera against Delta was moderately reduced. Delta was resistant to imdevimab, which, however, might be circumvented by combination therapy with casirivimab together. MDPI 2021-08-26 /pmc/articles/PMC8473269/ /pubmed/34578275 http://dx.doi.org/10.3390/v13091693 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Wilhelm, Alexander Toptan, Tuna Pallas, Christiane Wolf, Timo Goetsch, Udo Gottschalk, Rene Vehreschild, Maria J. G. T. Ciesek, Sandra Widera, Marek Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title | Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title_full | Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title_fullStr | Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title_full_unstemmed | Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title_short | Antibody-Mediated Neutralization of Authentic SARS-CoV-2 B.1.617 Variants Harboring L452R and T478K/E484Q |
title_sort | antibody-mediated neutralization of authentic sars-cov-2 b.1.617 variants harboring l452r and t478k/e484q |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473269/ https://www.ncbi.nlm.nih.gov/pubmed/34578275 http://dx.doi.org/10.3390/v13091693 |
work_keys_str_mv | AT wilhelmalexander antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT toptantuna antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT pallaschristiane antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT wolftimo antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT goetschudo antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT gottschalkrene antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT vehreschildmariajgt antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT cieseksandra antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q AT wideramarek antibodymediatedneutralizationofauthenticsarscov2b1617variantsharboringl452randt478ke484q |